Author/Editor		Dvoršak, Benjamin; Hojs, Radovan
Title		Hiperhomocisteinemija pri hemodializnih bolnikih
Translated title		Hyperhomocysteinemia in hemodialysis patients
Type		članek
Source		In: Buturović-Ponikvar J, Bren AF, editors. Zbornik 2. slovenski nefrološki kongres z mednarodno udeležbo ob 30. letnici dialize in transplantacije ledvic v Sloveniji; 2000 sep 27-30; Brdo pri Kranju. Ljubljana: Klinični center, Klinični oddelek za nefrologijo,
Publication year		2000
Volume		str. 237-42
Language		slo
Abstract		Background. Cardiovascular disease is major cause of morbidity and mortality in hemodialysis patients. Hyperhomocysteinemia is now recognised as an independent risk factor for cardiovascular disease. It was reported that plasma homocysteine levels are markedly elevated in hemodialysis patients, hyperhomocysteinemia was found in 75% to 85% dialysis patients. The aim of the study was to assess whether hemodialysis patients treated in our unit have elevated homocysteine levels compared with healthy subjects. Methods. A total of 34 patients (23 men and 11 woman) with end-stage renal disease treated with hemodialysis, and 34 healthy subjects matched with the patients with respect of to age and gender (control group) were enrolled in the study. Mean age was 38,2 +- 9,8 years and mean duration of dialysis treatment was 66,0 +- 55,2 months. Plasma total homocysteine was determined by enzyme immunoassay. Results. Mean plasma homocysteine level was 44,1 +- 22,8 mmol/l in hemodialysis patients and 9,0 +- 1,6 mmol/I in control group. Homocysteine levels in hemodialysis patients were statistically significant (P<0,01) higher. Homocysteine levels were above 15 mmol/I (upper normal value) in all hemodialysis patients and no control group participant had homocysteine level above 15 mmol/I. Conclusions. Serum homocysteine levels were significantly higher in hemodialysis patients compared with healthy subjects. Hyperhomo-cysteinemia was present in all in the study included hemodialysis patients.
Descriptors		HEMODIALYSIS HOMOCYSTEINE CARDIOVASCULAR DISEASES